One Greenway Plaza
28 articles with DNAtrix, Inc.
Stephen Dilly Appointed as Chairman of Board of Directors
DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
DNX-2401 and Pembrolizumab Combination Shows Clinical Benefit in Recurrent Glioblastoma
DNAtrix to Present Updated Results from the Phase 2 CAPTIVE / KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
DNAtrix's oncolytic virus technology will be highlighted across six additional abstracts selected for presentation.
DNAtrix's Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial
The first-in-human Phase 1 study is evaluating the safety and efficacy of DNX-2440 to patients with recurrent glioblastoma for whom surgery is not possible or planned.
Multiple Studies of DNAtrix Oncolytic Viruses to be Presented at the SNO Annual Meeting
DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer
R&D collaboration to develop enhanced vaccines using DNAtrix's clinical stage viruses and Valo's proprietary antigenic peptide technology.
Effectiveness of DNAtrix's DNX-2440 Oncolytic Virus Expressing OX40L in Solid Tumors to be Presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer
DNAtrix announced today that MD Anderson Cancer Center collaborator, Juan Fueyo, MD, will present preclinical results for DNX-2440, an armed oncolytic adenovirus that expresses OX40 ligand (OX40L) in infected tumor cells, at the upcoming 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, DC from November 7th - 11th.
Treatment of Pediatric Brain Tumor, DIPG, with Oncolytic Adenovirus DNX-2401 to be Presented at the 2018 International Symposium for Pediatric Neuro-Oncology
DNAtrix announced today that Sonia Tejada, MD, PhD, neurosurgeon and investigator at Clínica Universidad de Navarra, will present updated clinical data from an ongoing trial of its oncolytic virus DNX-2401 (tasadenoturev) for pediatric diffuse midline gliomas.
The open-label, dose-escalating study is evaluating the safety and efficacy of single dose DNX-2401 for pediatric patients with newly diagnosed DIPG at the Clínica Universidad de Navarra in Pamplona, Spain.
Data MATRIX team is about to start two new projects in the United States and Europe.
Mechanism of Action Studies for DNAtrix's Oncolytic Virus DNX-2401 Presented at the 2017 Society for Neuro-Oncology Annual Meeting
Juan Fueyo, MD, Professor in the Department of Neuro-Oncology at MD Anderson Cancer Center, gave an oral presentation of clinical results showing that DNX-2401 therapy for high grade malignant glioma leads to a reduction in the expression of TIM3, a key marker of T-cell exhaustion and negative regulator of antitumor immunity.
DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting
Juan Fueyo, MD, Professor at MD Anderson Cancer Center Department of Neuro-Oncology, presented results of a comprehensive study on the oncolytic virus Delta-24-RGDOX at the 2017 Society for Immunotherapy of Cancer (SITC) Meeting, held in National Harbor, MD on November 10th - 12th.
DNAtrix, Inc. Announces Successful Intratumoral Delivery Of DNX-2401 Via Alcyone's MEMS Cannula For The Targeted Treatment Of Recurrent Glioblastoma
DNAtrix, Inc.'s Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation For Treating Malignant Brain Tumors